A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Latest Information Update: 12 Jul 2024
At a glance
- Drugs Galcanezumab (Primary) ; Rimegepant
- Indications Migraine
- Focus Therapeutic Use
- Acronyms CHALLENGE-MIG
- Sponsors Eli Lilly and Company
- 22 Aug 2023 Status changed from active, no longer recruiting to completed.
- 16 Jun 2023 According to Eli Lilly and Company Media Release, Lilly will disclose the full results of the CHALLENGE-MIG trial later this year.
- 16 Jun 2023 Primary endpoint (Mean Monthly Percentage of Participants with a 50% Response Rate) has not been met as per Eli Lilly and Company Media Release